ClinVar Miner

Submissions for variant NM_000083.3(CLCN1):c.434-2_434dup

dbSNP: rs753470655
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000550058 SCV000636331 pathogenic Congenital myotonia, autosomal recessive form; Congenital myotonia, autosomal dominant form 2024-01-10 criteria provided, single submitter clinical testing This variant, c.434-2_434dup, results in the insertion of 1 amino acid(s) of the CLCN1 protein (p.Ala145dup), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (rs753470655, gnomAD 0.007%). This variant has been observed in individual(s) with clinical features of autosomal recessive myotonia congenita (PMID: 31544778; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant has been reported in individual(s) with autosomal dominant myotonia congenita (PMID: 31544778); however, the role of the variant in this condition is currently unclear. This variant is also known as c.434-5_434-4insGCA. ClinVar contains an entry for this variant (Variation ID: 462844). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
MGZ Medical Genetics Center RCV002289753 SCV002581038 uncertain significance Congenital myotonia, autosomal recessive form 2022-07-12 criteria provided, single submitter clinical testing
Athena Diagnostics Inc RCV002473050 SCV002771104 likely pathogenic not provided 2022-04-04 criteria provided, single submitter clinical testing The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). In our internal patient population, this variant is statistically more frequent than in the general population, which is weak evidence this variant may be disease causing. This variant has been seen heterozygous and compound heterozygous in at least one individual with clinical features associated with this gene. This variant is also referred to as c.434-5_434-4insGCA in published literature. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Computational tools yielded predictions that this variant is unlikely to have an effect on normal RNA splicing.
Revvity Omics, Revvity Omics RCV002473050 SCV003830732 uncertain significance not provided 2023-02-10 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002289753 SCV004241525 likely pathogenic Congenital myotonia, autosomal recessive form 2023-12-15 criteria provided, single submitter clinical testing Variant summary: CLCN1 c.434-2_434dupAGC is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Two predict the variant weakens a 3 acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 2.4e-05 in 251114 control chromosomes. c.434-2_434dupAGC has been reported in the literature in individuals affected with Myotonia congenita. These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 31544778, 34529042). Four submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Multiple submitters reported the variant with conflicting assessments (likely pathogenic n=2, VUS n=2). Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.